Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

D-Pharm

Request full access

Medicines for Degenerative and Age-Related Disorders

Rehovot, IsraelFounded 1993Biotech & Life Sciences

About D-Pharm

Established in April 1993 by Dr. Alex Kozak, D-Pharm is a specialty pharmaceutical company headquartered in Rehovot, Israel, that focuses on developing proprietary drugs for brain disorders. The company operates from its facilities in the Kiryat Weizmann Science Park, which include research and development laboratories and a pilot manufacturing plant. The firm's strategy centers on its two proprietary platform technologies designed to create lipid-like medicines that interact with specific cellular pathways. These efforts have produced a portfolio of New Chemical Entities safeguarded by a range of international patents.

D-Pharm's business model revolves around the research, development, and subsequent commercialization of its drug candidates. The company has a history of advancing products through clinical trials, such as DP-b99 for stroke and DP-VPA for epilepsy, both of which reached Phase II clinical development. The company has also explored additional therapeutic applications for its main candidates, including traumatic brain injury and bipolar disorder. Its pipeline has also included pre-clinical candidates for conditions like Alzheimer's disease. Historically, the company secured capital through various funding rounds, including early-stage venture capital in 1995 and 1997, later-stage rounds, and an IPO in 2009. Over its history, D-Pharm has raised significant funding from a pool of investors that includes Apax Partners, Care Capital, and Clal Biotechnology Industries. The company was acquired in March 2018.

The company's primary market is the global pharmaceutical industry, with a specific focus on therapeutics for central nervous system (CNS) disorders. Its clients are larger pharmaceutical companies that can take its developed drugs through late-stage trials and to market. One such example is the agreement with Shire Pharmaceuticals for the development and marketing of DP-VPA. After its acquisition, the company also became involved with cannabis-based products for international distribution. This positions the firm within both the traditional drug discovery and the emerging cannabis life sciences sectors.

Source: Dealroom company data

D-Pharm in the Rehovot ecosystem

Live from Dealroom

The D-Pharm office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later8 investors entered at this stage

  • Care Capital
  • Gemini Israel Ventures
  • Ramius
  • Cowen Group
  • Vertex Holdings
  • Rho Ventures
  • Denali Ventures
  • IQVIA
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇮🇱 Israel · Rehovot HQ
Book a demo for the full country breakdown

See D-Pharm on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.